Beyond productivity: How gen AI is improving decision-making in pharma and healthcare

When pharma leaders talk about generative AI (Artificial Intelligence), the conversation quickly turns to productivity, fewer manual tasks, and smaller teams. However, while the productivity benefits are real, they only scratch the surface of what this technology can actually do.

The bigger opportunity of generative AI in pharma lies in decision-making, and that is where the real competitive advantage will be won. 

From task automation to insight generation

Nearly every company will soon be seen using generative AI to handle routine work. However, the organizations that will actually pull ahead will be the ones using it to generate better insights that drive smarter choices. 

Here are a few areas beyond task automation where gen AI can create a positive impact:

• Drug discovery: AI can help companies sift through large volumes of complex biological data to identify promising molecules and spot connections that would take human researchers much longer to find.
• Clinical trial protocols: Writing a trial protocol is slow, detailed work that can take up a lot of time. Gen AI can streamline parts of this process, giving research teams more time for the science itself.
• Predicting patient drop-off: AI can use synthetic data to predict which patients might leave a trial early, giving organizations a chance to step in before it affects results.
• Regulatory submissions: As generative AI capabilities continue to improve, it can help pharma companies prepare regulatory documentation faster and with fewer errors.
• Data moats: By allowing companies to make sense of diverse, large-scale data, generative AI can help build data-driven competitive advantages.

Getting the foundations right

While the potential of generative AI in pharma beyond productivity is clear, building long-term capability requires the right setup. Organizations need strong cloud infrastructure, scalable AI systems, and people who know how to manage them effectively. 

This is where healthcare data analytics consulting can play an important role by helping teams select the right model, customize them for business needs, and ensure data privacy and security.

Overall, the organizations that treat gen AI as a strategic investment rather than a productivity tool are likely to see the biggest returns. The window to build that foundation is open right now. The question is -who moves first?